华润双鹤(600062.SH)子公司DC6001片获得药物临床试验批准通知书

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., has received the Drug Clinical Trial Approval Notice for DC6001 tablets from the National Medical Products Administration. The DC6001 tablets are intended for the treatment of Stargardt disease, a hereditary macular degeneration condition in adolescents [1]. Group 1 - The company has received regulatory approval for a new drug candidate [1] - The drug candidate DC6001 is aimed at treating a specific genetic condition affecting the youth [1] - This development may enhance the company's portfolio in the ophthalmology sector [1]